Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26277
Title: | Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 |
Authors: | Cavalcanti AB Zampieri FG Rosa RG Azevedo LCP Veiga VC Avezum A Damiani LP Marcadenti A Kawano-Dourado L Lisboa T Junqueira DLM de Barros e Silva PGM Tramujas L Abreu-Silva EO Laranjeira LN Soares AT Echenique LS Pereira AJ Freitas FGR Gebara OCE Dantas VCS Furtado RHM Milan EP Golin NA Cardoso FF Maia IS Hoffmann Filho CR Kormann APM Amazonas RB Bocchi de Oliveira MF Serpa-Neto A Falavigna M Lopes RD Machado FR Berwanger O |
Keywords: | Adult;Aged;Aged, 80 and over;Antiviral Agents;Azithromycin;Betacoronavirus;Brazil;COVID-19;Coronavirus Infections;Drug Therapy, Combination;Female;Hospitalization;Humans;Hydroxychloroquine;Male;Middle Aged;Pandemics;Patient Acuity;Pneumonia, Viral;SARS-CoV-2;Treatment Failure |
Publication Date: | 19-Nov-2020 |
Publisher: | Massachusetts Medical Society |
Citation: | Cavalcanti, Alexandre B., et al. “Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.” New England Journal of Medicine, vol. 383, no. 21, Massachusetts Medical Society, July 2020, pp. 2041–52, doi:10.1056/NEJMoa2019014. |
Abstract: | BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS: We conducted a multicenter, randomized, open-label, three-group, controlled trial involving hospitalized patients with suspected or confirmed Covid-19 who were receiving either no supplemental oxygen or a maximum of 4 liters per minute of supplemental oxygen. Patients were randomly assigned in a 1:1:1 ratio to receive standard care, standard care plus hydroxychloroquine at a dose of 400 mg twice daily, or standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days. The primary outcome was clinical status at 15 days as assessed with the use of a seven-level ordinal scale (with levels ranging from one to seven and higher scores indicating a worse condition) in the modified intention-to-treat population (patients with a confirmed diagnosis of Covid-19). Safety was also assessed. RESULTS: A total of 667 patients underwent randomization; 504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P = 1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P = 1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. CONCLUSIONS: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. (Funded by the Coalition Covid-19 Brazil and EMS Pharma; ClinicalTrials.gov number, NCT04322123.). |
URI: | http://hdl.handle.net/11375/26277 |
metadata.dc.identifier.doi: | https://doi.org/10.1056/nejmoa2019014 |
ISSN: | 0028-4793 1533-4406 |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.pdf | Published version | 642.49 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.